JP2024535930A - Ｔｒｏｐ２発現腫瘍細胞を標的化する結合剤 - Google Patents

Ｔｒｏｐ２発現腫瘍細胞を標的化する結合剤 Download PDF

Info

Publication number
JP2024535930A
JP2024535930A JP2024519706A JP2024519706A JP2024535930A JP 2024535930 A JP2024535930 A JP 2024535930A JP 2024519706 A JP2024519706 A JP 2024519706A JP 2024519706 A JP2024519706 A JP 2024519706A JP 2024535930 A JP2024535930 A JP 2024535930A
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
set forth
binding agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024519706A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024535930A5 (enExample
Inventor
ウェンヤン・ホウ
シュガン・ヤオ
ルイス・ダ・クルス
デイヴィッド・エス・ヤング
Original Assignee
キソジ・バイオテクノロジー・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キソジ・バイオテクノロジー・インコーポレイテッド filed Critical キソジ・バイオテクノロジー・インコーポレイテッド
Publication of JP2024535930A publication Critical patent/JP2024535930A/ja
Publication of JP2024535930A5 publication Critical patent/JP2024535930A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024519706A 2021-09-29 2022-09-28 Ｔｒｏｐ２発現腫瘍細胞を標的化する結合剤 Pending JP2024535930A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163249728P 2021-09-29 2021-09-29
US63/249,728 2021-09-29
US202263326572P 2022-04-01 2022-04-01
US63/326,572 2022-04-01
PCT/CA2022/051437 WO2023049999A1 (en) 2021-09-29 2022-09-28 Binding agents targeting trop2-expressing tumor cells

Publications (2)

Publication Number Publication Date
JP2024535930A true JP2024535930A (ja) 2024-10-02
JP2024535930A5 JP2024535930A5 (enExample) 2025-10-08

Family

ID=85780298

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024519706A Pending JP2024535930A (ja) 2021-09-29 2022-09-28 Ｔｒｏｐ２発現腫瘍細胞を標的化する結合剤

Country Status (10)

Country Link
US (4) US12662549B2 (enExample)
EP (1) EP4408893A4 (enExample)
JP (1) JP2024535930A (enExample)
KR (1) KR20240082383A (enExample)
AU (1) AU2022357634A1 (enExample)
CA (1) CA3231574A1 (enExample)
IL (1) IL311673A (enExample)
MX (1) MX2024003779A (enExample)
TW (1) TW202330605A (enExample)
WO (1) WO2023049999A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024003779A (es) 2021-09-29 2024-04-19 Kisoji Biotechnology Inc Agentes de union dirigidos a celulas tumorales que expresan trop2.
EP4688866A1 (en) * 2023-04-04 2026-02-11 Kisoji Biotechnology Inc. Binding agents targeting trop2-expressing tumor cells
WO2024051383A1 (zh) * 2023-07-28 2024-03-14 上海洛启生物医药技术有限公司 抗Trop2抗体、包含所述抗体的缀合物及其应用
WO2026059880A1 (en) * 2024-09-12 2026-03-19 Modernatx, Inc. Trop2 binding molecules, nucleic acids encoding same, and methods of use
CN122145634A (zh) * 2026-05-11 2026-06-05 上海荣昌生物科技有限公司 一种cd47抗体

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111518212A (zh) * 2020-04-16 2020-08-11 上海洛启生物医药技术有限公司 抗Trop2纳米抗体及其应用
CN112321715A (zh) * 2020-11-03 2021-02-05 博奥信生物技术（南京）有限公司 抗trop2纳米抗体及其制备方法和应用
WO2021068949A1 (zh) * 2019-10-11 2021-04-15 迈威(上海)生物科技股份有限公司 抗人Trop-2抗体及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201500220A1 (ru) 2010-05-17 2015-10-30 Ливтех, Инк. Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo
WO2011155579A1 (ja) 2010-06-10 2011-12-15 北海道公立大学法人札幌医科大学 抗Ｔｒｏｐ－２抗体
US9427464B2 (en) 2011-11-22 2016-08-30 Chiome Bioscience Inc. Anti-human TROP-2 antibody having an antitumor activity in vivo
EP3256494A4 (en) 2015-02-10 2018-12-05 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
RU2758234C2 (ru) * 2017-03-27 2021-10-26 Иммьюномедикс, Инк. ЛЕЧЕНИЕ ТРИЖДЫ НЕГАТИВНОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ, ХАРАКТЕРИЗУЮЩЕГОСЯ ЭКСПРЕССИЕЙ Trop-2, С ПОМОЩЬЮ САЦИТУЗУМАБА ГОВИТЕКАНА И ИНГИБИТОРА Rad51
GB201811368D0 (en) * 2018-07-11 2018-08-29 Ucb Biopharma Sprl Antibody
CA3171363A1 (en) 2019-12-20 2021-06-24 Kisoji Biotechnology Inc. Polypeptides, protein complexes and method for making same
CN114685669A (zh) 2020-12-30 2022-07-01 和铂医药(苏州)有限公司 结合trop2的抗体及其用途
MX2024003779A (es) 2021-09-29 2024-04-19 Kisoji Biotechnology Inc Agentes de union dirigidos a celulas tumorales que expresan trop2.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021068949A1 (zh) * 2019-10-11 2021-04-15 迈威(上海)生物科技股份有限公司 抗人Trop-2抗体及其应用
CN111518212A (zh) * 2020-04-16 2020-08-11 上海洛启生物医药技术有限公司 抗Trop2纳米抗体及其应用
CN112321715A (zh) * 2020-11-03 2021-02-05 博奥信生物技术（南京）有限公司 抗trop2纳米抗体及其制备方法和应用

Also Published As

Publication number Publication date
US20240317886A1 (en) 2024-09-26
US12338295B2 (en) 2025-06-24
TW202330605A (zh) 2023-08-01
WO2023049999A1 (en) 2023-04-06
US20240360242A1 (en) 2024-10-31
US20240317887A1 (en) 2024-09-26
MX2024003779A (es) 2024-04-19
US20240327537A1 (en) 2024-10-03
KR20240082383A (ko) 2024-06-10
US12275799B2 (en) 2025-04-15
US12371508B2 (en) 2025-07-29
AU2022357634A1 (en) 2024-05-09
US12662549B2 (en) 2026-06-23
IL311673A (en) 2024-05-01
CA3231574A1 (en) 2023-04-06
EP4408893A4 (en) 2026-02-18
EP4408893A1 (en) 2024-08-07

Similar Documents

Publication Publication Date Title
US12275799B2 (en) Binding agents targeting TROP2-expressing tumor cells
JP7858665B2 (ja) Ｒｏｒ１およびｃｄ３に対する特異性を有する多重特異性抗体
AU2019356806B2 (en) Antibody constructs binding 4-1BB and tumor-associated antigens and uses thereof
US10836833B2 (en) Cell engaging binding molecules
WO2022121928A1 (zh) 抗egfr的纳米抗体及其用途
EP4324853A1 (en) Multi-specific antibody targeting bcma
US20230265202A1 (en) Antibody constructs binding 4-1bb and folate receptor alpha and uses thereof
WO2024165031A1 (zh) 三特异性抗原结合分子及其应用
KR20250143344A (ko) 항-cdh6 항체 및 이의 용도
CN115348971A (zh) 抗体-药物缀合物
JP2025539455A (ja) 抗ｔｆｒ１抗体及びその使用
KR20260007641A (ko) Trop2를 발현하는 종양 세포를 표적으로 하는 결합제
CN118159566A (zh) 靶向表达trop2的肿瘤细胞的结合剂
WO2024088386A1 (en) Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
WO2025242212A1 (en) Anti-sstr2 antibodies
HK40120932A (en) Antibody, and drug conjugate and use thereof
CN116761823A (zh) 靶向gpc3和cd47的双特异性抗体
AU2024233425A1 (en) Anti-cd3 multispecific antibodies and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250929

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260707

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20260730